Renal Cancer - Results from #1760

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. November 16, 2021

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation. November 16, 2021

The The Prognosis and Immune Microenvironment Related Factor Interleukin-23 in Clear Cell Renal Cell Carcinoma: A Radiological Investigation. November 15, 2021

[Synchronous oligometastatic renal cell carcinoma-what is the role of surgery?] November 15, 2021

Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma November 12, 2021

Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma. November 12, 2021

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. November 12, 2021

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. November 11, 2021

ROBOCOP II (ROBOtic assisted versus conventional open partial nephrectomy) randomised, controlled feasibility trial: clinical trial protocol. November 11, 2021

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial November 10, 2021

The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. November 10, 2021

Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient? November 10, 2021

Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy. November 9, 2021

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. November 9, 2021

Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). November 8, 2021

Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. November 8, 2021

Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. November 8, 2021

External Validation of the ASSURE Model for Predicting Oncological Outcomes After Resection of High-risk Renal Cell Carcinoma (RESCUE Study: UroCCR 88). November 5, 2021

Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. November 4, 2021

Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. November 4, 2021

Page 89 of 456